Determining The Impacts Of Epigenetic Modifying Drugs On Germline Programming And Offspring Health
Funder
National Health and Medical Research Council
Funding Amount
$863,918.00
Summary
New drugs have been developed that inhibit specific enzymes that regulate epigenetic pathways in cells. These pathways significantly affect growth and development in offspring and may represent a risk to future children of patients taking the drug. This project will determine these risks and provide data for developing clinical guidelines for safe use of the drugs.
Perturbation of the extracellular architecture to promote the absorption and lymphatic transport of biological macromolecules. Macromolecules therapeutics such as proteins, antibodies or polymer conjugates pose a number of pharmaceutical challenges. Where the dose is high, drainage of that dose from a subcutaneous injection site into the circulation, poses a particular problem. Here the project aims to explore how recombinant hyaluronidase, an enzyme that breaks down a structural component (hya ....Perturbation of the extracellular architecture to promote the absorption and lymphatic transport of biological macromolecules. Macromolecules therapeutics such as proteins, antibodies or polymer conjugates pose a number of pharmaceutical challenges. Where the dose is high, drainage of that dose from a subcutaneous injection site into the circulation, poses a particular problem. Here the project aims to explore how recombinant hyaluronidase, an enzyme that breaks down a structural component (hyaluronan) of the interstitum, can be used promote absorption into the draining blood and lymph capillaries. The project aims to also explore the downstream effects of hyaluronidase on lymph nodes and evaluate whether the enzyme is able to temporarily disrupt the lymph node structure and promote drug penetration into the lymph node mass. This has significant potential for improved drug targeting.Read moreRead less
Understanding the Cellular Pathways of Nuclear Receptor Activation. The success of drug treatment depends critically on specificity, i.e., stimulation of a therapeutic response at a target site, and avoidance of activity at other (potentially toxic) locations. This project aims to explore how drug interactions with binding proteins in the cytosol can induce nuclear transport and tissue specific activation of nuclear receptors - a major drug target. The project intends to employ molecular, struct ....Understanding the Cellular Pathways of Nuclear Receptor Activation. The success of drug treatment depends critically on specificity, i.e., stimulation of a therapeutic response at a target site, and avoidance of activity at other (potentially toxic) locations. This project aims to explore how drug interactions with binding proteins in the cytosol can induce nuclear transport and tissue specific activation of nuclear receptors - a major drug target. The project intends to employ molecular, structural and cell biology approaches to map drug-binding protein-receptor interactions and to determine how the structure of these complexes dictates receptor activation. The data could provide a roadmap to design drugs that interact with the right protein in the right tissue and in doing so dramatically enhance drug specificity.Read moreRead less
Discovery Early Career Researcher Award - Grant ID: DE120103084
Funder
Australian Research Council
Funding Amount
$375,000.00
Summary
Targeting bacterial superbugs: novel approaches for optimisation of antibiotic combinations and resistance prevention. This project will elucidate the mechanistic basis to optimally combine available beta-lactam antibiotics to prevent resistance of gram-negative 'superbugs'. The interdisciplinary project will substantially contribute to solving the global crisis due to multidrug-resistant bacteria and inform the design of effective new antibiotics.
Targeting an impending global disaster: the mismatch between increasingly drug-resistant superbugs and development of new antibiotics. This project will develop much-needed novel antibiotics for treating infections caused by bacteria that are resistant to all current antibiotics. It will make a significant contribution to the global medical challenge of a shortage of new antibiotics.
Light-responsive nanomaterials as nanomedicines: new approaches to treating macular degeneration, cancer and other critical unmet therapeutic needs. Nanotechnology is enabling new medicines for the treatment of important diseases such as cancer and macular degeneration. This project will investigate novel nanomaterials for the development of new highly effective medicines that can be controlled after administration, leading to reduced side effects and increased convenience for patients.
Controlling the spatial distribution of targeting ligands on dendrimer surfaces as a means of dictating cellular recognition and fate. This project seeks to develop next generation targeted drug delivery systems that 'home' to specific target cells, including cancers. Targeted delivery systems have the potential to revolutionise therapy by providing bespoke drug distribution patterns that are tailored to specific diseases and result in enhanced activity and reduced toxicity.
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE0668493
Funder
Australian Research Council
Funding Amount
$230,000.00
Summary
Characterising particulate laden flow in the lung airways: from drug delivery to primary anthropogenic sources. Facilities will provide infrastructure at Monash University and University of Sydney to continue the collaboration enhancing excellence in an exciting application of fluidics research, supporting the highest level of graduate training, providing innovative tools for industry and promoting industrial collaborations. The infrastructure is unique and will create international funding and ....Characterising particulate laden flow in the lung airways: from drug delivery to primary anthropogenic sources. Facilities will provide infrastructure at Monash University and University of Sydney to continue the collaboration enhancing excellence in an exciting application of fluidics research, supporting the highest level of graduate training, providing innovative tools for industry and promoting industrial collaborations. The infrastructure is unique and will create international funding and collaborative opportunities to support research and postgraduate training. The equipment will add value to existing infrastructure to enhance understanding of particulate flow with the paradoxical outcomes of improving drug deposition in respiratory delivery and of minimising anthropogenic particular deposition for better therapeutic and health outcomes.Read moreRead less
Powder blending for dry powder inhalers: a new approach for direct control of powder structure. Over 80 per cent of pharmaceutical products involve the processing of powders. This project will generate new knowledge of how to assemble fine and cohesive particles into the structure required for dry powder inhaler products, leading to the development of new low-cost medicines in Australia and the Asia Pacific region.
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE0560661
Funder
Australian Research Council
Funding Amount
$245,300.00
Summary
Particulate Characterisation for Pharmaceutical and Engineering Applications. The aim of this proposal is to establish joint facilities between the University of Sydney, Monash University and UNSW for the characterization of surface properties and particle sizes of pharmaceutical aerosols and industrial powders. Such knowledge is important for controlling aerosol production and delivery of drug particles to the lungs. This will have a significant benefit to the pharmaceutical industry and patien ....Particulate Characterisation for Pharmaceutical and Engineering Applications. The aim of this proposal is to establish joint facilities between the University of Sydney, Monash University and UNSW for the characterization of surface properties and particle sizes of pharmaceutical aerosols and industrial powders. Such knowledge is important for controlling aerosol production and delivery of drug particles to the lungs. This will have a significant benefit to the pharmaceutical industry and patients requiring aerosol treatment. Further, the proposed facilities will enhance research in complex particulate processes and modelling, functional nanomaterials, and soft sensor development, thus keeping Australia at the forefront of powder research into various high value adding particulate areas.Read moreRead less